University Connection
Connecting You to the University of Maryland
At the BioPark, we place the power of the University of Maryland’s research enterprise and clinical care at your doorstep, fostering connections that advance your ventures.
-
$1.3 billion
in research awards (Fiscal Year 2025)
-
#9
among all public U.S. research universities (National Science Foundation | Higher Education Research and Development Survey Fiscal Year 2024, Released December 2025)
-
300
bioscience and pharmaceutical collaborators
The University of Maryland, Baltimore (UMB), our partner institution, is a thriving academic health center for biomedical research. Within the University’s internationally recognized centers and institutes, renowned experts are conducting cutting-edge research, generating discoveries, and creating innovative technologies that advance human health.
Through its joint research enterprise with the University of Maryland, College Park, UMB offers unique opportunities for collaboration in areas such as bioengineering, cyber technology, health informatics and data science, medical device development, business, and law.
Sharing UMB’s campus are the University of Maryland Medical Center (UMMC) and the Baltimore VA Medical Center, clinical partners that participate in cutting-edge research and clinical trials. UMMC is a national and regional referral center for trauma, cancer care, neurocare, cardiac care, diabetes and endocrinology, women's and children's health and has one of the largest solid organ transplant programs in the country.
Featured Company
KaloCyte
Pre-clinical biotech company KaloCyte is developing a novel bio-inspired artificial red blood cell substitute for use as a lifeline when blood is not available. Co-founded by Allan Doctor, MD, director of the University of Maryland School of Medicine’s (UMSOM) Center for Blood Oxygen Transport and Hemostasis, KaloCyte is working closely with UMSOM to develop a shelf-stable whole blood equivalent.
University of Maryland, Baltimore’s Research Enterprise
With six nationally ranked professional schools – medicine, pharmacy, dentistry, nursing, law, and social work – and an interdisciplinary graduate school, UMB offers a strong foundation for powerful research and collaboration.
Industry Partnership
The University of Maryland, Baltimore collaborates with pharma, biotech, medtech, and other healthcare companies across basic, translational, and clinical studies. To learn more about partnering with the University to accelerate scientific discovery and deliver real-world impact through strategic innovation, visit the University of Maryland School of Medicine's Business Development site.
Select research strengths:
- Oncology
- Cellular Immunotherapy
- Clinical Trials/Translation
- Drug Design and Formulation
- Cardiovascular Device Development
- Genomics
- HIV/AIDS
- Infectious diseases
- Neurology/Neurosurgery
- Nanobiotechnology
- Pain
- Stem Cell Biology and Regenerative Medicine
- Vaccine and Adjuvant Development
- Vascular Biology
- Radiology/Imaging
- Dentistry
- Trauma
- Transplant Surgery
- Regulatory Science
- Trauma
- Transplant Surgery
- Regulatory Science
Select centers of excellence:
- Center for Shock, Trauma and Anesthesiology Research
- Center for Stem Cell Biology and Regenerative Medicine
- Center for Vaccine Development and Global Health (CVD)
- Center for Vascular and Inflammatory Diseases
- Institute for Genome Sciences
- Institute for Health Computing
- Institute of Human Virology
- Kahlert Institute for Addiction Medicine
- UM Marlene and Stewart Greenebaum Comprehensive Cancer Center
- Computer-Aided Drug Design Center
- Pharmaceutical Research Computing
Moving Discovery Out of the Lab
UMB fuels the creation of innovative start-up companies and attracts industry-leaders and entrepreneurs to its thriving downtown campus. The expert commercialization team works closely with the University’s inventors to advance their discoveries, spinning out 10 new start-ups each year and executing more than 40 licenses.
Learn more about UMB’s technology commercialization arm, UM Ventures, Baltimore.